SLC45A3-ELK4 mRNA expression was later confirmed in prostate cancer samples, as well as in LNCaP cells, and five different mRNA variants of the chimeric transcript were described (Rickman et al., 2009). This evidence concerns the gene SLC45A3 and prostate cancer.